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Maine Center for Disease Control and Prevention (Maine CDC)  
annually publishes a report on infectious diseases in Maine. This report 
is prepared by the Division of Disease Surveillance and is intended to 
provide an overview of notifiable infectious diseases of public health 
importance in Maine. 
We could not produce this report without the continued support of  
our healthcare and public health partners throughout the state. We 
greatly appreciate all of the laboratories, healthcare providers, childcare 
centers, school nurses, veterinarians, and others who provide disease 
surveillance information. Partners spend considerable time assisting 
Maine CDC with infectious disease investigations and disease control 
measures that affect Maine residents. Public health partners’ active  
and critical role in the infectious disease surveillance cycle informs 
statewide policies and programs that protect our residents from 
infectious diseases through health promotion, disease prevention,  
early detection, containment, and treatment. 
We appreciate and encourage your vigilance in the effort to protect  
the people of Maine through timely, complete, and accurate notifiable 
infectious disease reporting. It is through these collaborative efforts 
that we are able to respond to emerging infectious disease threats and 
prevent outbreaks. 
We hope you find this report useful as we all work to protect  
and promote the health of Maine’s residents. As always, we welcome 
your feedback on how we can provide more useful disease information 
to you, our partners. 
For more information on what, when, and how to report infectious 
diseases please see the Notifiable Diseases and Conditions List  
(Page 73) of this report, visit our website at www.maine.gov/idepi or  
call 1-800-821-5821. 
Ann Farmer, MS
Associate Director, Division of Disease 
Surveillance
Maine Center for Disease Control  
and Prevention
THANK YOU
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2018 INFECTIOUS DISEASE  
SURVEILLANCE HIGHLIGHTS
4
Mosquito pools tested positive 
for West Nile Virus (WNV)
69 104
185 25%
Increase from 2017
Reported cases of 
infectious syphilis in 2018
People with hepatitis C 
identified as at risk for 
hepatitis B.
Maine CDC sponsored a hepatitis 
A vaccine clinic in response to a 
confirmed case of hepatitis A in a 
person experiencing homelessness.
Received a hep A vaccine
Bangor is the farthest north Maine 
detected WNV in a mosquito pool
Disease reports investigated  
by Maine CDC staff including  
STD cases.
Potential outbreaks investigated  
by Maine CDC staff. 
Disease reports handled without 
a full investigation by staff, either 
through passive surveillance or 
laboratory reports.*
4,879 
3,647 
Met a probable or 
confirmed case  
definition.
344
254
Classified as  
outbreaks.
9,757
7,963
Met a probable or  
confirmed case  
definition.
*The main diseases include chlamydia, hepatitis C, Lyme disease, rabies post-exposure prophylaxis, 
and some varicella and invasive MRSA cases.
Maine CDC 
initiated contact 
with providers 
to recommend 
vaccination.
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1,000+ 
Influenza-related 
hospitalizations
100+
Influenza-related outbreaks  
during the 2018-2019 flu season
10,300+ 
Positive influenza 
reports
45+ 
Influenza-related  
deaths
2018 INFECTIOUS DISEASE  
SURVEILLANCE HIGHLIGHTS
21 76
Reported pertussis  
outbreaks
Animals tested positive  
for rabies at HETL
3,620
2018 Maine CDC Infectious  
Disease Program consults
TOP 5 
Rabies (32%), influenza, pertussis, 
tuberculosis, and varicella
10%
of all consults occurred in August
85
52%
Increase  
from 2017
Reported cases of  
Group A Streptococcus
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CONDITION 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Anaplasma 
phagocytophilum
15 17 26 52 94 191 185 372 663 476
Babesiosis 3 5 9 10 36 42 55 82 118 101
Brucellosis 0 2 0 0 0 0 0 0 1 0
Campylobacteriosis 172 148 195 189 229 225 221 255 234 247
Carbapenem-resistant 
Enterobacteriaceae (CRE)***
NR NR NR NR NR NR 12 51 58 92
Chikungunya Virus NA NA 0 0 1 6 2 0 1 2
Chlamydia trachomatis 
infection
2443 2588 3101 3413 3440 3491 3851 4152 4555 4346
Creutzfeldt-Jakob Disease 
(CJD)
1 0 0 0 1 1 1 0 0 0
Cryptosporidiosis 67 93 51 58 35 51 34 55 45 60
Cyclosporiasis 0 1 0 0 0 7 1 3 0 0
Dengue 3 6 0 0 1 1 5 2 0 3
Eastern Equine Encephalitis 0 0 0 0 0 1 1 0 0 0
Ehrlichiosis, chaffeensis 1 4 1 3 3 8 5 7 10 19
Giardiasis 223 223 171 169 218 154 116 137 129 163
Gonorrhea 143 163 273 456 246 236 422 444 577 686
Group A Streptococcus, 
invasive
21 47 43 37 37 53 56 60 56 85
Haemophilus influenzae, 
invasive
21 13 26 23 25 21 39 29 34 24
Hantavirus infection, non-
Hantavirus pulmonary 
syndromes
0 0 1 0 0 0 0 0 0 0
Hemolytic uremic syndrome 2 1 2 2 2 1 7 2 2 0
Hepatitis A, acute 1 7 6 9 10 8 8 8 7 9
Hepatitis B, acute 15 13 8 9 11 12 9 53 77 52
Hepatitis B, chronic 125 102 105 105 106 108 107 159 179 201
Hepatitis C, acute 2 2 12 12 9 31 29 37 32 39
Hepatitis C, chronic 1112 1016 1085 1151 1235 1409 1444 1648 1878 1872
Hepatitis D, acute 0 1 1 0 0 0 0 0 0 0
Hepatitis E, acute 0 0 1 0 0 0 0 1 0 0
HIV Infection 51 57 51 46 33 61 48 53 29 30
Influenza Associated 
Pediatric Mortality
0 0 0 0 0 1 0 1 0 0
Invasive Pneumococcal 
Disease
168 151 136 102 121 137 135 133 141 132
Legionellosis 10 12 18 18 23 19 16 16 16 34
COUNTS OF SELECTED*  
REPORTABLE DISEASES BY YEAR
MAINE, 2009-2018**
NR = not reportable; NA = not available
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CONDITION 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Listeriosis 4 1 4 5 4 8 7 11 5 7
Lyme disease 976 752 1013 1113 1384 1411 1215 1498 1855 1405
Malaria 2 6 6 5 10 7 7 10 18 9
Measles (Rubeola) 0 0 0 0 0 0 0 0 1 0
Mumps 6 2 2 0 1 0 0 34 1 4
Neisseria meningitidis, 
invasive (Mening. disease)
4 5 5 3 4 2 4 1 1 1
Novel Influenza A virus 
Infections
2219 17 3 0 0 0 0 0 0 0
Pertussis 80 53 205 737 332 557 281 259 411 446
Powassan 0 0 0 0 1 0 1 1 3 0
Q fever 0 0 2 0 0 0 0 0 0 1
Rabies PEP 59 77 145 190 128 107 112 131 108 152
Rabies, animal 63 67 66 91 50 44 28 66 61 76
S. aureus, methicillin 
resistant (MRSA), invasive
123 90 121 116 130 143 191 178 180 243
S. aureus, vancomycin 
intermediate resistance 
(VISA)
0 0 0 0 0 1 2 1 0 0
Salmonellosis 121 135 134 161 131 127 123 123 102 119
Shellfish poisoning 1 0 0 0 0 0 0 0 0 0
Shiga toxin-producing 
Escherichia coli (STEC)
19 21 28 20 27 33 29 37 34 37
Shigellosis 5 8 32 7 5 29 4 2 13 7
Spotted Fever Rickettsiosis 5 2 1 3 2 3 1 4 3 10
Syphilis 14 40 19 20 17 15 49 48 83 104
Tetanus 0 0 0 0 1 0 0 1 1 0
Trichinosis (Trichinellosis) 0 1 1 0 0 0 0 0 0 0
Tuberculosis 9 8 9 17 15 14 18 23 14 14
Varicella (Chickenpox) 235 247 226 258 140 207 233 228 198 252
Vibriosis 4 5 4 10 9 9 6 7 7 14
West Nile 0 0 0 1 0 0 1 0 0 2
 
• Anthrax
• Botulism
• California Serogroup viruses
• Chancroid
• Coronavirus
• Diphtheria
• Hepatitis D, chronic
• Leptospirosis
• Plague
• Polio
• Psittacosis
• Rabies, human
• Ricin
• Rubella
• Smallpox
• Saint Louis Encephalitis
• Tularemia
• Viral Hemorrhagic Fever
• Western Equine Encephalitis
• Yellow Fever
 * Maine did not have any cases of the following reportable conditions in the last ten years:
 ** Counts are updated annually . Data as of 6/5/2018
 *** CRE became reportable as of September 8, 2015 so the 2015 numbers do not represent a full year
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CONDITION 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Anaplasma phagocytophilum 1.1 1.3 2.0 3.9 7.1 14.4 13.9 27.9 49.6 35.6
Babesiosis 0.2 0.4 0.7 0.8 2.7 3.2 4.1 6.2 8.8 7.5
Brucellosis 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0
Campylobacteriosis 13.0 11.1 14.7 14.2 17.2 16.9 16.6 19.2 17.5 18.5
Carbapenem-resistant 
Enterobacteriaceae (CRE)***
NR NR NR NR NR NR 0.9 3.8 4.3 6.9
Chikungunya Virus NA NA 0.0 0.0 0.1 0.5 0.2 0.0 0.1 0.1
Chlamydia trachomatis 
infection
185.3 194.9 233.5 256.8 258.8 262.3 289.7 311.8 341.0 324.7
Creutzfeldt-Jakob Disease 
(CJD)
0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0
Cryptosporidiosis 5.1 7.0 3.8 4.4 2.6 3.8 2.6 4.1 3.4 4.5
Cyclosporiasis 0.0 0.1 0.0 0.0 0.0 0.5 0.1 0.2 0.0 0.0
Dengue 0.2 0.5 0.0 0.0 0.1 0.1 0.4 0.2 0.0 0.2
Eastern Equine Encephalitis 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0
Ehrlichiosis, chaffeensis 0.1 0.3 0.1 0.2 0.2 0.6 0.4 0.5 0.7 1.4
Giardiasis 16.9 16.8 12.9 12.7 16.4 11.6 8.7 10.3 9.7 12.2
Gonorrhea 10.8 12.3 20.6 34.3 18.5 17.7 31.7 33.3 43.2 51.3
Group A Streptococcus, 
invasive
1.6 3.5 3.2 2.8 2.8 4.0 4.2 4.5 4.2 6.4
Haemophilus influenzae, 
invasive
1.6 1.0 2.0 1.7 1.9 1.6 2.9 2.2 2.5 1.8
Hantavirus infection, non-
Hantavirus pulmonary 
syndromes
0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Hemolytic uremic syndrome 0.2 0.1 0.2 0.2 0.2 0.1 0.5 0.2 0.1 0.0
Hepatitis A, acute 0.1 0.5 0.5 0.7 0.8 0.6 0.6 0.6 0.5 0.7
Hepatitis B, acute 1.1 1.0 0.6 0.7 0.8 0.9 0.7 4.0 5.8 3.9
Hepatitis B, chronic 9.5 7.7 7.9 7.9 8.0 8.1 8.0 11.9 13.4 15.0
Hepatitis C, acute 0.2 0.2 0.9 0.9 0.7 2.3 2.2 2.8 2.4 2.9
Hepatitis C, chronic 84.4 76.5 81.7 86.6 92.9 105.9 108.6 123.8 140.6 139.9
Hepatitis D, acute 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Hepatitis E, acute 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0
HIV Infection 3.9 4.3 3.8 3.5 2.5 4.6 3.6 4.0 2.2 2.2
Influenza Associated Pediatric 
Mortality
0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0
Invasive Pneumococcal 
Disease
12.7 11.4 10.2 7.7 9.1 10.3 10.2 10.0 10.6 9.9
Legionellosis 0.8 0.9 1.4 1.4 1.7 1.4 1.2 1.2 1.2 2.5
RATES OF SELECTED*  
REPORTABLE DISEASES BY YEAR
MAINE, 2009-2018**  
(PER 100,000 PERSONS)
NR = not reportable; NA = not available
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CONDITION 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Listeriosis 0.3 0.1 0.3 0.4 0.3 0.6 0.5 0.8 0.4 0.5
Lyme disease 74.0 56.6 76.3 83.8 104.1 106.0 91.4 112.5 138.9 105.0
Malaria 0.2 0.5 0.5 0.4 0.8 0.5 0.5 0.8 1.3 0.7
Measles (Rubeola) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0
Mumps 0.5 0.2 0.2 0.0 0.1 0.0 0.0 2.6 0.1 0.3
Neisseria meningitidis, invasive 
(Mening. disease)
0.3 0.4 0.4 0.2 0.3 0.2 0.3 0.1 0.1 0.1
Novel Influenza A virus 
Infections
168.3 1.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Pertussis 6.1 4.0 15.4 55.5 25.0 41.9 21.1 19.5 30.8 33.3
Powassan 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0
Q fever 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1
Rabies PEP 4.5 5.8 10.9 14.3 9.6 8.0 8.4 9.8 8.1 11.4
Rabies, animal NA NA NA NA NA NA NA NA NA NA
S. aureus, methicillin resistant 
(MRSA), invasive
9.3 6.8 9.1 8.7 9.8 10.7 14.4 13.4 13.5 18.2
S. aureus, vancomycin 
intermediate resistance (VISA)
0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0
Salmonellosis 9.2 10.2 10.1 12.1 9.9 9.5 9.3 9.2 7.6 8.9
Shellfish poisoning 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Shiga toxin-producing 
Escherichia coli (STEC)
1.4 1.6 2.1 1.5 2.0 2.5 2.2 2.8 2.5 2.8
Shigellosis 0.4 0.6 2.4 0.5 0.4 2.2 0.3 0.2 1.0 0.5
Spotted Fever Rickettsiosis 0.4 0.2 0.1 0.2 0.2 0.2 0.1 0.3 0.2 0.7
Syphilis 1.1 3.0 1.4 1.5 1.3 1.1 3.7 3.6 6.2 7.8
Tetanus 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0
Trichinosis (Trichinellosis) 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Tuberculosis 0.7 0.6 0.7 1.3 1.1 1.1 1.4 1.7 1.0 1.0
Varicella (Chickenpox) 17.8 18.6 17.0 19.4 10.5 15.6 17.5 17.1 14.8 18.8
Vibriosis 0.3 0.4 0.3 0.8 0.7 0.7 0.5 0.5 0.5 1.0
West Nile 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1
• Anthrax
• Botulism
• California Serogroup viruses
• Chancroid
• Coronavirus
• Diphtheria
• Hepatitis D, chronic
• Leptospirosis
• Plague
• Polio
• Psittacosis
• Rabies, human
• Ricin
• Rubella
• Smallpox
• Saint Louis Encephalitis
• Tularemia
• Viral Hemorrhagic Fever
• Western Equine Encephalitis
• Yellow Fever
 * Maine did not have any cases of the following reportable conditions in the last ten years:
 ** Counts are updated annually . Data as of 6/5/2018
 *** CRE became reportable as of September 8, 2015 so the 2015 numbers do not represent a full year
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GENDER AGE GROUP
CONDITION F M
0-5 
years
5-14 
years
15-24 
years
25-34 
years
35-44 
years
45-54 
years
55-64 
years
65+ 
years
Anaplasma phagocytophilum 178 298 5 10 8 16 32 67 114 224
Babesiosis 28 73 0 2 2 4 7 14 21 51
Borrelia miyamotoi 5 3 0 1 0 1 1 0 2 3
Campylobacteriosis 112 135 11 13 14 34 25 40 40 70
Carbapenem-resistant Enterobacteriaceae 
(CRE)
60 32 0 3 2 2 1 12 11 61
Chikungunya Virus 1 1 0 0 0 0 1 1 0 0
Chlamydia trachomatis infection 2854 1492 866 10 2299 921 183 48 14 5
Coccidioidomycosis 1 1 0 0 0 0 1 0 0 1
Cryptosporidiosis 38 22 3 10 10 12 7 5 6 7
Dengue 2 1 0 0 1 0 1 1 0 0
Ehrlichiosis, chaffeensis 10 9 1 1 1 1 0 5 1 9
Ehrlichiosis/Anaplasmosis, undetermined 6 3 0 1 2 0 1 2 0 3
Emerging Infection 0 1 0 0 0 0 0 1 0 0
Giardiasis 72 91 5 10 20 17 19 22 36 34
Gonorrhea 246 440 0 2 239 243 114 53 32 3
Group A Streptococcus, invasive 32 53 1 2 3 12 9 7 7 44
Haemophilus influenzae, invasive 15 9 3 2 1 1 0 2 6 9
Hepatitis A, acute 5 4 0 0 0 1 2 1 3 2
Hepatitis B, acute 22 30 0 0 2 9 23 13 5 0
Hepatitis B, chronic 63 138 2 3 9 44 63 38 22 20
Hepatitis C, acute 17 22 0 0 3 14 15 6 1 0
Hepatitis C, chronic 824 1048 6 3 200 577 373 228 295 190
HIV 7 23 0 0 3 11 8 4 3 1
Invasive Pneumococcal Disease 69 63 4 1 1 7 9 18 32 60
Jamestown Canyon virus 1 0 0 0 0 0 0 0 0 1
Legionellosis 15 19 0 0 0 1 3 8 7 15
Listeriosis 4 3 0 0 0 0 0 1 1 5
Lyme disease 604 801 60 192 91 82 112 165 281 422
CASES OF REPORTED DISEASES  
BY AGE AND GENDER 
MAINE, 2018
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GENDER AGE GROUP
CONDITION F M
0-5 
years
5-14 
years
15-24 
years
25-34 
years
35-44 
years
45-54 
years
55-64 
years
65+ 
years
Malaria 5 4 0 1 3 1 1 2 1 0
Mumps 1 3 1 0 1 1 1 0 0 0
Neisseria meningitidis,  
invasive (Mening. disease)
1 0 1 0 0 0 0 0 0 0
Pertussis 215 231 147 177 87 7 9 6 7 6
Q fever 0 1 0 0 0 0 0 0 0 1
Rabies PEP 94 58 12 10 16 28 23 26 18 19
Rabies, animal NA NA NA NA NA NA NA NA NA NA
S. aureus, methicillin resistant (MRSA), 
invasive
94 149 2 3 6 32 24 25 38 113
Salmonellosis 61 58 7 9 9 14 10 20 20 30
Shiga toxin-producing Escherichia coli 
(STEC)
24 13 7 1 9 4 6 1 4 5
Shigellosis 3 4 1 0 3 1 1 0 1 0
Spotted Fever Rickettsiosis 4 6 0 1 1 3 2 0 2 1
Streptococcal toxic-shock syndrome 5 7 1 0 0 1 1 1 1 7
Syphilis 8 96 0 0 15 36 13 30 7 3
Tuberculosis 4 10 1 1 2 3 2 2 1 2
Varicella (Chickenpox) 144 108 58 59 15 18 14 15 24 49
Vibriosis 4 10 0 0 1 3 1 1 1 7
WNV, Non-Human NA NA NA NA NA NA NA NA NA NA
West Nile Fever 1 1 0 0 0 0 0 0 1 1
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RACE ETHNICITY
CONDITION
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Anaplasma phagocytophilum 2 2 1 460 0 0 11 5 424 47
Babesiosis 0 1 0 99 0 0 1 0 97 4
Borrelia miyamotoi 0 0 0 7 0 0 1 0 7 1
Campylobacteriosis 1 1 2 233 0 0 10 3 226 18
Carbapenem-resistant Enterobacteriaceae 
(CRE)
0 1 1 69 0 1 20 0 58 34
Chikungunya Virus 0 0 0 2 0 0 0 0 1 1
Chlamydia trachomatis infection 26 37 248 2632 6 148 1249 46 2167 2133
Coccidioidomycosis 0 0 0 2 0 0 0 0 2 0
Cryptosporidiosis 1 1 0 57 0 0 1 1 58 1
Dengue 0 0 0 3 0 0 0 0 3 0
Ehrlichiosis, chaffeensis 0 0 0 17 0 0 2 0 17 2
Ehrlichiosis/Anaplasmosis, undetermined 0 0 0 8 0 0 1 0 9 0
Emerging Infection 0 0 0 1 0 0 0 0 0 1
Giardiasis 0 1 8 147 0 0 7 1 148 14
Gonorrhea 5 7 117 497 16 17 27 24 578 84
Group A Streptococcus, invasive 0 0 2 79 0 2 2 1 79 5
Haemophilus influenzae, invasive 0 1 0 22 0 0 1 0 23 1
Hepatitis A, acute 0 0 0 9 0 0 0 1 7 1
Hepatitis B, acute 3 0 0 48 1 0 0 0 52 0
Hepatitis B, chronic 1 14 68 102 1 5 10 3 173 25
Hepatitis C, acute 2 0 1 33 0 0 3 0 34 5
Hepatitis C, chronic 7 3 23 1110 9 38 682 10 688 1174
HIV 1 1 5 23 0 0 0 2 28 0
Invasive Pneumococcal Disease 1 1 1 127 0 0 2 1 123 8
Jamestown Canyon virus 0 0 0 1 0 0 0 0 1 0
Legionellosis 0 0 0 31 0 0 3 0 30 4
Listeriosis 0 0 0 6 0 0 1 0 6 1
CASES OF REPORTED DISEASES  
BY RACE AND ETHNICITY 
MAINE, 2018
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RACE ETHNICITY
CONDITION
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Lyme disease 0 3 4 1172 0 0 226 6 513 886
Malaria 0 0 7 1 0 0 1 0 6 3
Mumps 0 0 0 3 0 0 1 1 3 0
Neisseria meningitidis,  
invasive (Mening. disease)
0 0 0 1 0 0 0 0 1 0
Pertussis 2 3 8 411 0 0 22 3 403 40
Q fever 0 0 0 1 0 0 0 0 1 0
Rabies PEP 0 1 0 114 0 2 35 1 92 59
Rabies, animal NA NA NA NA NA NA NA NA NA NA
S. aureus, methicillin resistant (MRSA), 
invasive
1 0 2 208 1 0 31 1 134 108
Salmonellosis 0 0 2 112 1 0 4 1 111 7
Shiga toxin-producing Escherichia coli 
(STEC)
0 1 0 31 0 0 5 1 30 6
Shigellosis 0 0 4 3 0 0 0 0 7 0
Spotted Fever Rickettsiosis 0 0 0 9 0 0 1 0 9 1
Streptococcal toxic-shock syndrome 0 0 0 12 0 0 0 0 12 0
Syphilis 1 1 4 89 2 1 6 1 82 21
Tuberculosis 0 2 8 4 0 0 0 0 14 0
Varicella (Chickenpox) 0 5 4 179 0 0 64 2 177 73
Vibriosis 0 0 0 13 0 0 1 0 13 1
WNV, Non-Human NA NA NA NA NA NA NA NA NA NA
West Nile Fever 0 0 0 2 0 0 0 0 2 0
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Outbreaks are a reportable condition in Maine and are classified into types of outbreak by the potential etiology. All reported 
outbreaks are assigned out for follow-up with a field epidemiologist. This table only represents those that met an outbreak 
definition of confirmed, probable, or suspect. Outbreak definitions vary based on the category, setting, and suspected etiology.
2018 MAINE OUTBREAKS 
OUTBREAK CATEGORIES AND DEFINITIONS
Absenteeism: Absenteeism reports are submitted by 
schools when they have ≥15% absenteeism due to illness.  
If there is a single etiology an absenteeism report may also 
be counted as a disease-specific outbreak. 
Airborne and Direct Contact (ADC): Airborne and Direct 
Contact outbreaks are transmitted through airborne 
bacteria or viruses or through direct contact. Examples of 
Airborne and Direct Contact outbreaks include pneumonia, 
conjunctivitis, hand foot and mouth disease, and MRSA.
Gastrointestinal Illness (GI): GI illness outbreaks are 
characterized through gastrointestinal symptoms. The most 
commonly reported GI outbreak is caused by norovirus. Out 
of state GI outbreaks are when a Maine resident matches 
a national cluster through Pulsed-field Gel Electrophoresis 
(PFGE) testing such as Salmonella or Shiga toxin producing  
E. coli (STEC).
Influenza-like Illness (ILI): Influenza-like illness outbreaks are 
characterized as a respiratory illness with fever and/or sore throat 
without another known cause. The majority of ILI outbreaks are 
confirmed as influenza through laboratory testing.
Other: Outbreaks in this category are not captured in 
any other group. Examples include C. difficile, multi-drug 
resistant organisms, or outbreaks caused by contaminated 
devices. 
Vaccine-Preventable Disease (VPD): Vaccine-preventable 
disease outbreaks are caused by one of the illnesses for 
which there is a routine vaccine. The most commonly 
reported VPD outbreak is caused by pertussis. Pertussis was 
the cause of all VPD outbreaks in 2018.
Varicella: Varicella (chickenpox) outbreaks are caused 
by chickenpox. An outbreak is defined as three or more 
confirmed cases in a single setting.
Vector: Vector outbreaks are caused by an organism that 
spreads infection from one host to another. The most 
common vectors in Maine are ticks and mosquitoes, but the 
most common vector outbreak is caused by scabies.
* ILI outbreaks included here are for the calendar year 2018, so includes outbreaks from the 2017-2018 and 2018-2019 influenza seasons.
Any outbreak can be healthcare associated.
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Absenteeism 1 0 1 0 4 1 1 2 0 1 0 0 0 3 5 2 1 22
ADC 1 0 2 0 0 0 0 0 0 0 1 0 0 0 1 0 1 6
GI 10 2 19 0 0 7 4 2 11 0 4 0 0 1 0 0 9 69
ILI 10 6 34 1 2 11 9 1 0 8 8 0 4 6 0 4 23 127
Other 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
VPD 1 0 3 0 4 0 0 0 0 0 1 0 1 0 2 0 9 21
Varicella 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 3 6
Vector 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 2
Total 23 8 62 1 10 19 14 5 11 9 15 0 5 10 8 7 47 254
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Since 2003, the Infectious Disease Programs of Maine CDC publish an annual summary of infectious disease data. Publishing 
reports on surveillance activities and data provides the health care community, government agencies, individuals, and groups 
with important statistical information on Maine’s reportable diseases and conditions. 
This annual report also includes information on conditions that are investigated that are not explicitly reportable but have 
public health significance. Examples of these conditions include Borrelia miyamotoi, Jamestown Canyon virus and Zika virus. 
Maine also follows up on unusual conditions that may not have specific case definitions but potentially have public health 
significance. These conditions are indicated by “Emerging Infections.” In 2018 the emerging infection was a report of alpha-gal 
allergy that Maine CDC is monitoring. The goal of this annual report is to provide Maine CDC’s partners with a helpful resource.
Maine CDC counts cases by their residence, not where they acquired the condition.
(Population data is from 2018 census estimates.)
PUBLIC DISTRICT HEALTH MAP
Aroostook
District 1
District 2
District 3
District 4
District 5
District 6
District 7
District 8
Piscataquis
Penobscot
Hancock
Washington
Somerset
Franklin
Waldo
Kennebec
Oxford
York
Sagadahoc 
Andro-
scoggin
Lincoln
Knox
Cumberland
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 31 28.8 48 24.6 476 35.6
Babesiosis 9 8.4 11 5.6 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 16 14.9 30 15.4 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
5 4.6 14 7.2 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 569 528.4 807 413.4 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 0 0.0 1 0.5 60 4.5
Dengue 1 0.9 1 0.5 3 0.2
Ehrlichiosis, chaffeensis 3 2.8 3 1.5 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 1 0.9 2 1.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 10 9.3 22 11.3 163 12.2
Gonorrhea 238 221.0 263 134.7 686 51.3
Group A Streptococcus, invasive 14 13.0 21 10.8 85 6.4
Haemophilus influenzae, invasive 2 1.9 5 2.6 24 1.8
Hepatitis A, acute 2 1.9 2 1.0 9 0.7
Hepatitis B, acute 1 0.9 1 0.5 52 3.9
Hepatitis B, chronic 25 23.2 31 15.9 201 15.0
107,679
Of Maine’s Total 
Population 
8.0%
Population
ANDROSCOGGIN COUNTY
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 3 2.8 4 2.0 39 2.9
Hepatitis C, chronic 124 115.2 200 102.5 1872 139.9
HIV 1 0.9 2 1.0 30 2.2
Invasive Pneumococcal Disease 10 9.3 17 8.7 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 3 2.8 7 3.6 34 2.5
Listeriosis 1 0.9 2 1.0 7 0.5
Lyme disease 68 63.2 128 65.6 1405 105.0
Malaria 2 1.9 2 1.0 9 0.7
Mumps 1 0.9 1 0.5 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
1 0.9 1 0.5 1 0.1
Pertussis 25 23.2 34 17.4 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 5 4.6 11 5.6 152 11.4
Rabies, animal 7 NA 15 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
14 13.0 29 14.9 243 18.2
Salmonellosis 8 7.4 14 7.2 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
1 0.9 2 1.0 37 2.8
Shigellosis 4 3.7 4 2.0 7 0.5
Spotted Fever Rickettsiosis 1 0.9 1 0.5 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 1 0.5 12 0.9
Syphilis 7 6.5 13 6.7 104 7.8
Tuberculosis 1 0.9 1 0.5 14 1.0
Varicella (Chickenpox) 9 8.4 15 7.7 252 18.8
Vibriosis 0 0.0 1 0.5 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 0 0.0 0 0.0 476 35.6
Babesiosis 0 0.0 0 0.0 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 23 34.3 23 34.3 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
1 1.5 1 1.5 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 171 254.8 171 254.8 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 2 3.0 2 3.0 60 4.5
Dengue 0 0.0 0 0.0 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 0 0.0 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 0 0.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 4 6.0 4 6.0 163 12.2
Gonorrhea 10 14.9 10 14.9 686 51.3
Group A Streptococcus, invasive 2 3.0 2 3.0 85 6.4
Haemophilus influenzae, invasive 1 1.5 1 1.5 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 0 0.0 0 0.0 52 3.9
Hepatitis B, chronic 3 4.5 3 4.5 201 15.0
67,111
Of Maine’s Total 
Population 
5.0%
Population
AROOSTOOK COUNTY
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 3 4.5 3 4.5 39 2.9
Hepatitis C, chronic 55 82.0 55 82.0 1872 139.9
HIV 2 3.0 2 3.0 30 2.2
Invasive Pneumococcal Disease 10 14.9 10 14.9 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 3 4.5 3 4.5 34 2.5
Listeriosis 1 1.5 1 1.5 7 0.5
Lyme disease 4 6.0 4 6.0 1405 105.0
Malaria 0 0.0 0 0.0 9 0.7
Mumps 0 0.0 0 0.0 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 1 1.5 1 1.5 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 6 8.9 6 8.9 152 11.4
Rabies, animal 1 NA 1 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
19 28.3 19 28.3 243 18.2
Salmonellosis 7 10.4 7 10.4 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
1 1.5 1 1.5 37 2.8
Shigellosis 0 0.0 0 0.0 7 0.5
Spotted Fever Rickettsiosis 0 0.0 0 0.0 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 0 0.0 12 0.9
Syphilis 0 0.0 0 0.0 104 7.8
Tuberculosis 0 0.0 0 0.0 14 1.0
Varicella (Chickenpox) 15 22.4 15 22.4 252 18.8
Vibriosis 0 0.0 0 0.0 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 71 24.2 71 24.2 476 35.6
Babesiosis 20 6.8 20 6.8 101 7.5
Borrelia miyamotoi 1 0.3 1 0.3 8 0.6
Campylobacteriosis 61 20.8 61 20.8 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
33 11.2 33 11.2 92 6.9
Chikungunya Virus 1 0.3 1 0.3 2 0.1
Chlamydia trachomatis infection 1050 357.7 1050 357.7 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 11 3.7 11 3.7 60 4.5
Dengue 1 0.3 1 0.3 3 0.2
Ehrlichiosis, chaffeensis 7 2.4 7 2.4 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 0 0.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 46 15.7 46 15.7 163 12.2
Gonorrhea 181 61.7 181 61.7 686 51.3
Group A Streptococcus, invasive 20 6.8 20 6.8 85 6.4
Haemophilus influenzae, invasive 8 2.7 8 2.7 24 1.8
Hepatitis A, acute 4 1.4 4 1.4 9 0.7
Hepatitis B, acute 15 5.1 15 5.1 52 3.9
Hepatitis B, chronic 93 31.7 93 31.7 201 15.0
293,557
Of Maine’s Total 
Population 
21.9%
Population
CUMBERLAND COUNTY
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 13 4.4 13 4.4 39 2.9
Hepatitis C, chronic 536 182.6 536 182.6 1872 139.9
HIV 9 3.1 9 3.1 30 2.2
Invasive Pneumococcal Disease 14 4.8 14 4.8 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 3 1.0 3 1.0 34 2.5
Listeriosis 0 0.0 0 0.0 7 0.5
Lyme disease 285 97.1 285 97.1 1405 105.0
Malaria 4 1.4 4 1.4 9 0.7
Mumps 0 0.0 0 0.0 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 57 19.4 57 19.4 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 22 7.5 22 7.5 152 11.4
Rabies, animal 17 NA 17 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
37 12.6 37 12.6 243 18.2
Salmonellosis 26 8.9 26 8.9 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
12 4.1 12 4.1 37 2.8
Shigellosis 0 0.0 0 0.0 7 0.5
Spotted Fever Rickettsiosis 1 0.3 1 0.3 10 0.7
Streptococcal toxic-shock syndrome 3 1.0 3 1.0 12 0.9
Syphilis 34 11.6 34 11.6 104 7.8
Tuberculosis 11 3.7 11 3.7 14 1.0
Varicella (Chickenpox) 73 24.9 73 24.9 252 18.8
Vibriosis 5 1.7 5 1.7 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 2 0.7 2 0.7 2 0.1
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 3 10.0 48 24.6 476 35.6
Babesiosis 0 0.0 11 5.6 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 4 13.4 30 15.4 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
1 3.3 14 7.2 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 72 240.8 807 413.4 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 0 0.0 1 0.5 60 4.5
Dengue 0 0.0 1 0.5 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 3 1.5 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 2 1.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 4 13.4 22 11.3 163 12.2
Gonorrhea 8 26.8 263 134.7 686 51.3
Group A Streptococcus, invasive 1 3.3 21 10.8 85 6.4
Haemophilus influenzae, invasive 0 0.0 5 2.6 24 1.8
Hepatitis A, acute 0 0.0 2 1.0 9 0.7
Hepatitis B, acute 0 0.0 1 0.5 52 3.9
Hepatitis B, chronic 1 3.3 31 15.9 201 15.0
29,897
Of Maine’s Total 
Population 
2.2%
Population
FRANKLIN COUNTY
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 0 0.0 4 2.0 39 2.9
Hepatitis C, chronic 16 53.5 200 102.5 1872 139.9
HIV 1 3.3 2 1.0 30 2.2
Invasive Pneumococcal Disease 3 10.0 17 8.7 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 3 10.0 7 3.6 34 2.5
Listeriosis 1 3.3 2 1.0 7 0.5
Lyme disease 13 43.5 128 65.6 1405 105.0
Malaria 0 0.0 2 1.0 9 0.7
Mumps 0 0.0 1 0.5 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 1 0.5 1 0.1
Pertussis 7 23.4 34 17.4 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 0 0.0 11 5.6 152 11.4
Rabies, animal 2 NA 15 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
6 20.1 29 14.9 243 18.2
Salmonellosis 3 10.0 14 7.2 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
0 0.0 2 1.0 37 2.8
Shigellosis 0 0.0 4 2.0 7 0.5
Spotted Fever Rickettsiosis 0 0.0 1 0.5 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 1 0.5 12 0.9
Syphilis 5 16.7 13 6.7 104 7.8
Tuberculosis 0 0.0 1 0.5 14 1.0
Varicella (Chickenpox) 4 13.4 15 7.7 252 18.8
Vibriosis 1 3.3 1 0.5 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 15 27.4 16 18.5 476 35.6
Babesiosis 5 9.1 6 7.0 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 12 21.9 16 18.5 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
0 0.0 1 1.2 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 126 229.9 220 254.9 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 2 3.6 3 3.5 60 4.5
Dengue 0 0.0 0 0.0 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 0 0.0 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 0 0.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 7 12.8 8 9.3 163 12.2
Gonorrhea 11 20.1 15 17.4 686 51.3
Group A Streptococcus, invasive 5 9.1 8 9.3 85 6.4
Haemophilus influenzae, invasive 0 0.0 1 1.2 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 7 12.8 12 13.9 52 3.9
Hepatitis B, chronic 5 9.1 15 17.4 201 15.0
HANCOCK COUNTY
54,811
Of Maine’s Total 
Population 
4.1%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 2 3.6 3 3.5 39 2.9
Hepatitis C, chronic 68 124.1 115 133.3 1872 139.9
HIV 4 7.3 4 4.6 30 2.2
Invasive Pneumococcal Disease 6 10.9 13 15.1 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 2 3.6 2 2.3 34 2.5
Listeriosis 0 0.0 0 0.0 7 0.5
Lyme disease 174 317.5 189 219.0 1405 105.0
Malaria 1 1.8 1 1.2 9 0.7
Mumps 0 0.0 0 0.0 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 31 56.6 32 37.1 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 2 3.6 12 13.9 152 11.4
Rabies, animal 3 NA 8 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
11 20.1 20 23.2 243 18.2
Salmonellosis 7 12.8 10 11.6 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
0 0.0 0 0.0 37 2.8
Shigellosis 0 0.0 0 0.0 7 0.5
Spotted Fever Rickettsiosis 1 1.8 2 2.3 10 0.7
Streptococcal toxic-shock syndrome 1 1.8 2 2.3 12 0.9
Syphilis 2 3.6 4 4.6 104 7.8
Tuberculosis 1 1.8 1 1.2 14 1.0
Varicella (Chickenpox) 9 16.4 13 15.1 252 18.8
Vibriosis 1 1.8 1 1.2 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 57 46.7 67 38.8 476 35.6
Babesiosis 5 4.1 5 2.9 101 7.5
Borrelia miyamotoi 2 1.6 2 1.2 8 0.6
Campylobacteriosis 25 20.5 33 19.1 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
7 5.7 8 4.6 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 364 298.2 518 300.0 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 5 4.1 12 6.9 60 4.5
Dengue 0 0.0 0 0.0 3 0.2
Ehrlichiosis, chaffeensis 6 4.9 6 3.5 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 4 3.3 4 2.3 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 12 9.8 20 11.6 163 12.2
Gonorrhea 47 38.5 59 34.2 686 51.3
Group A Streptococcus, invasive 7 5.7 10 5.8 85 6.4
Haemophilus influenzae, invasive 0 0.0 0 0.0 24 1.8
Hepatitis A, acute 0 0.0 2 1.2 9 0.7
Hepatitis B, acute 1 0.8 2 1.2 52 3.9
Hepatitis B, chronic 4 3.3 6 3.5 201 15.0
KENNEBEC COUNTY
122,083
Of Maine’s Total 
Population 
9.1%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 0 0.0 3 1.7 39 2.9
Hepatitis C, chronic 147 120.4 212 122.8 1872 139.9
HIV 2 1.6 4 2.3 30 2.2
Invasive Pneumococcal Disease 18 14.7 24 13.9 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 3 2.5 5 2.9 34 2.5
Listeriosis 1 0.8 2 1.2 7 0.5
Lyme disease 181 148.3 226 130.9 1405 105.0
Malaria 1 0.8 1 0.6 9 0.7
Mumps 0 0.0 1 0.6 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 15 12.3 26 15.1 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 15 12.3 23 13.3 152 11.4
Rabies, animal 9 NA 10 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
25 20.5 34 19.7 243 18.2
Salmonellosis 7 5.7 10 5.8 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
5 4.1 7 4.1 37 2.8
Shigellosis 0 0.0 0 0.0 7 0.5
Spotted Fever Rickettsiosis 3 2.5 3 1.7 10 0.7
Streptococcal toxic-shock syndrome 1 0.8 1 0.6 12 0.9
Syphilis 9 7.4 14 8.1 104 7.8
Tuberculosis 0 0.0 0 0.0 14 1.0
Varicella (Chickenpox) 12 9.8 22 12.7 252 18.8
Vibriosis 0 0.0 0 0.0 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 88 221.3 182 121.8 476 35.6
Babesiosis 17 42.7 30 20.1 101 7.5
Borrelia miyamotoi 1 2.5 5 3.3 8 0.6
Campylobacteriosis 6 15.1 27 18.1 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
2 5.0 11 7.4 92 6.9
Chikungunya Virus 0 0.0 1 0.7 2 0.1
Chlamydia trachomatis infection 114 286.6 385 257.6 4346 324.7
Coccidioidomycosis 1 2.5 2 1.3 2 0.1
Cryptosporidiosis 0 0.0 8 5.4 60 4.5
Dengue 0 0.0 1 0.7 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 0 0.0 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 2 1.3 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 7 17.6 24 16.1 163 12.2
Gonorrhea 7 17.6 32 21.4 686 51.3
Group A Streptococcus, invasive 1 2.5 4 2.7 85 6.4
Haemophilus influenzae, invasive 0 0.0 1 0.7 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 2 5.0 2 1.3 52 3.9
Hepatitis B, chronic 4 10.1 17 11.4 201 15.0
KNOX COUNTY
39,771
Of Maine’s Total 
Population 
3.0%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 1 2.5 1 0.7 39 2.9
Hepatitis C, chronic 96 241.4 214 143.2 1872 139.9
HIV 2 5.0 4 2.7 30 2.2
Invasive Pneumococcal Disease 4 10.1 15 10.0 132 9.9
Jamestown Canyon virus 1 2.5 1 0.7 1 0.1
Legionellosis 1 2.5 2 1.3 34 2.5
Listeriosis 0 0.0 0 0.0 7 0.5
Lyme disease 105 264.0 292 195.4 1405 105.0
Malaria 0 0.0 0 0.0 9 0.7
Mumps 0 0.0 0 0.0 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 3 7.5 87 58.2 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 11 27.7 27 18.1 152 11.4
Rabies, animal 2 NA 16 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
7 17.6 26 17.4 243 18.2
Salmonellosis 3 7.5 19 12.7 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
0 0.0 6 4.0 37 2.8
Shigellosis 0 0.0 1 0.7 7 0.5
Spotted Fever Rickettsiosis 3 7.5 3 2.0 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 0 0.0 12 0.9
Syphilis 2 5.0 9 6.0 104 7.8
Tuberculosis 0 0.0 0 0.0 14 1.0
Varicella (Chickenpox) 4 10.1 20 13.4 252 18.8
Vibriosis 2 5.0 2 1.3 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
32   |   2018 Reportable Infectious Diseases Summary
Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 44 128.1 182 121.8 476 35.6
Babesiosis 5 14.6 30 20.1 101 7.5
Borrelia miyamotoi 3 8.7 5 3.3 8 0.6
Campylobacteriosis 9 26.2 27 18.1 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
5 14.6 11 7.4 92 6.9
Chikungunya Virus 1 2.9 1 0.7 2 0.1
Chlamydia trachomatis infection 92 267.9 385 257.6 4346 324.7
Coccidioidomycosis 0 0.0 2 1.3 2 0.1
Cryptosporidiosis 1 2.9 8 5.4 60 4.5
Dengue 0 0.0 1 0.7 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 0 0.0 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 1 2.9 2 1.3 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 8 23.3 24 16.1 163 12.2
Gonorrhea 4 11.6 32 21.4 686 51.3
Group A Streptococcus, invasive 0 0.0 4 2.7 85 6.4
Haemophilus influenzae, invasive 1 2.9 1 0.7 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 0 0.0 2 1.3 52 3.9
Hepatitis B, chronic 5 14.6 17 11.4 201 15.0
LINCOLN COUNTY
34,342
Of Maine’s Total 
Population 
2.6%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 0 0.0 1 0.7 39 2.9
Hepatitis C, chronic 38 110.7 214 143.2 1872 139.9
HIV 1 2.9 4 2.7 30 2.2
Invasive Pneumococcal Disease 2 5.8 15 10.0 132 9.9
Jamestown Canyon virus 0 0.0 1 0.7 1 0.1
Legionellosis 1 2.9 2 1.3 34 2.5
Listeriosis 0 0.0 0 0.0 7 0.5
Lyme disease 62 180.5 292 195.4 1405 105.0
Malaria 0 0.0 0 0.0 9 0.7
Mumps 0 0.0 0 0.0 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 5 14.6 87 58.2 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 6 17.5 27 18.1 152 11.4
Rabies, animal 2 NA 16 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
7 20.4 26 17.4 243 18.2
Salmonellosis 6 17.5 19 12.7 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
0 0.0 6 4.0 37 2.8
Shigellosis 0 0.0 1 0.7 7 0.5
Spotted Fever Rickettsiosis 0 0.0 3 2.0 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 0 0.0 12 0.9
Syphilis 1 2.9 9 6.0 104 7.8
Tuberculosis 0 0.0 0 0.0 14 1.0
Varicella (Chickenpox) 5 14.6 20 13.4 252 18.8
Vibriosis 0 0.0 2 1.3 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
34   |   2018 Reportable Infectious Diseases Summary
Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 14 24.3 48 24.6 476 35.6
Babesiosis 2 3.5 11 5.6 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 10 17.4 30 15.4 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
8 13.9 14 7.2 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 166 288.1 807 413.4 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 1 1.7 1 0.5 60 4.5
Dengue 0 0.0 1 0.5 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 3 1.5 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 1 1.7 2 1.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 8 13.9 22 11.3 163 12.2
Gonorrhea 17 29.5 263 134.7 686 51.3
Group A Streptococcus, invasive 6 10.4 21 10.8 85 6.4
Haemophilus influenzae, invasive 3 5.2 5 2.6 24 1.8
Hepatitis A, acute 0 0.0 2 1.0 9 0.7
Hepatitis B, acute 0 0.0 1 0.5 52 3.9
Hepatitis B, chronic 5 8.7 31 15.9 201 15.0
OXFORD COUNTY
57,618
Of Maine’s Total 
Population 
4.3%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 1 1.7 4 2.0 39 2.9
Hepatitis C, chronic 60 104.1 200 102.5 1872 139.9
HIV 0 0.0 2 1.0 30 2.2
Invasive Pneumococcal Disease 4 6.9 17 8.7 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 1 1.7 7 3.6 34 2.5
Listeriosis 0 0.0 2 1.0 7 0.5
Lyme disease 47 81.6 128 65.6 1405 105.0
Malaria 0 0.0 2 1.0 9 0.7
Mumps 0 0.0 1 0.5 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 1 0.5 1 0.1
Pertussis 2 3.5 34 17.4 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 6 10.4 11 5.6 152 11.4
Rabies, animal 6 NA 15 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
9 15.6 29 14.9 243 18.2
Salmonellosis 3 5.2 14 7.2 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
1 1.7 2 1.0 37 2.8
Shigellosis 0 0.0 4 2.0 7 0.5
Spotted Fever Rickettsiosis 0 0.0 1 0.5 10 0.7
Streptococcal toxic-shock syndrome 1 1.7 1 0.5 12 0.9
Syphilis 1 1.7 13 6.7 104 7.8
Tuberculosis 0 0.0 1 0.5 14 1.0
Varicella (Chickenpox) 2 3.5 15 7.7 252 18.8
Vibriosis 0 0.0 1 0.5 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
36   |   2018 Reportable Infectious Diseases Summary
Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 8 5.3 8 4.8 476 35.6
Babesiosis 2 1.3 2 1.2 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 24 15.9 28 16.7 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
6 4.0 6 3.6 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 558 369.3 601 358.0 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 11 7.3 14 8.3 60 4.5
Dengue 0 0.0 0 0.0 3 0.2
Ehrlichiosis, chaffeensis 2 1.3 2 1.2 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 0 0.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 19 12.6 22 13.1 163 12.2
Gonorrhea 49 32.4 49 29.2 686 51.3
Group A Streptococcus, invasive 15 9.9 15 8.9 85 6.4
Haemophilus influenzae, invasive 4 2.6 4 2.4 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 10 6.6 12 7.1 52 3.9
Hepatitis B, chronic 20 13.2 20 11.9 201 15.0
PENOBSCOT COUNTY
151,096
Of Maine’s Total 
Population 
11.3%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 7 4.6 8 4.8 39 2.9
Hepatitis C, chronic 237 156.9 265 157.8 1872 139.9
HIV 2 1.3 2 1.2 30 2.2
Invasive Pneumococcal Disease 18 11.9 21 12.5 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 5 3.3 7 4.2 34 2.5
Listeriosis 1 0.7 1 0.6 7 0.5
Lyme disease 77 51.0 80 47.6 1405 105.0
Malaria 0 0.0 0 0.0 9 0.7
Mumps 1 0.7 1 0.6 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 35 23.2 36 21.4 446 33.3
Q fever 0 0.0 1 0.6 1 0.1
Rabies PEP 13 8.6 13 7.7 152 11.4
Rabies, animal 3 NA 5 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
44 29.1 46 27.4 243 18.2
Salmonellosis 8 5.3 9 5.4 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
1 0.7 1 0.6 37 2.8
Shigellosis 2 1.3 2 1.2 7 0.5
Spotted Fever Rickettsiosis 0 0.0 0 0.0 10 0.7
Streptococcal toxic-shock syndrome 2 1.3 2 1.2 12 0.9
Syphilis 7 4.6 8 4.8 104 7.8
Tuberculosis 1 0.7 1 0.6 14 1.0
Varicella (Chickenpox) 39 25.8 40 23.8 252 18.8
Vibriosis 1 0.7 1 0.6 14 1.0
WNV, Non-Human 2 NA 2 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 0 0.0 8 4.8 476 35.6
Babesiosis 0 0.0 2 1.2 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 4 23.8 28 16.7 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
0 0.0 6 3.6 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 43 256.0 601 358.0 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 3 17.9 14 8.3 60 4.5
Dengue 0 0.0 0 0.0 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 2 1.2 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 0 0.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 3 17.9 22 13.1 163 12.2
Gonorrhea 0 0.0 49 29.2 686 51.3
Group A Streptococcus, invasive 0 0.0 15 8.9 85 6.4
Haemophilus influenzae, invasive 0 0.0 4 2.4 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 2 11.9 12 7.1 52 3.9
Hepatitis B, chronic 0 0.0 20 11.9 201 15.0
PISCATAQUIS COUNTY
16,800
Of Maine’s Total 
Population 
1.3%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 1 6.0 8 4.8 39 2.9
Hepatitis C, chronic 28 166.7 265 157.8 1872 139.9
HIV 0 0.0 2 1.2 30 2.2
Invasive Pneumococcal Disease 3 17.9 21 12.5 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 2 11.9 7 4.2 34 2.5
Listeriosis 0 0.0 1 0.6 7 0.5
Lyme disease 3 17.9 80 47.6 1405 105.0
Malaria 0 0.0 0 0.0 9 0.7
Mumps 0 0.0 1 0.6 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 1 6.0 36 21.4 446 33.3
Q fever 1 6.0 1 0.6 1 0.1
Rabies PEP 0 0.0 13 7.7 152 11.4
Rabies, animal 2 NA 5 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
2 11.9 46 27.4 243 18.2
Salmonellosis 1 6.0 9 5.4 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
0 0.0 1 0.6 37 2.8
Shigellosis 0 0.0 2 1.2 7 0.5
Spotted Fever Rickettsiosis 0 0.0 0 0.0 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 2 1.2 12 0.9
Syphilis 1 6.0 8 4.8 104 7.8
Tuberculosis 0 0.0 1 0.6 14 1.0
Varicella (Chickenpox) 1 6.0 40 23.8 252 18.8
Vibriosis 0 0.0 1 0.6 14 1.0
WNV, Non-Human 0 NA 2 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
40   |   2018 Reportable Infectious Diseases Summary
Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 27 75.8 182 121.8 476 35.6
Babesiosis 2 5.6 30 20.1 101 7.5
Borrelia miyamotoi 1 2.8 5 3.3 8 0.6
Campylobacteriosis 6 16.8 27 18.1 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
2 5.6 11 7.4 92 6.9
Chikungunya Virus 0 0.0 1 0.7 2 0.1
Chlamydia trachomatis infection 101 283.4 385 257.6 4346 324.7
Coccidioidomycosis 1 2.8 2 1.3 2 0.1
Cryptosporidiosis 3 8.4 8 5.4 60 4.5
Dengue 0 0.0 1 0.7 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 0 0.0 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 1 2.8 2 1.3 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 3 8.4 24 16.1 163 12.2
Gonorrhea 9 25.3 32 21.4 686 51.3
Group A Streptococcus, invasive 1 2.8 4 2.7 85 6.4
Haemophilus influenzae, invasive 0 0.0 1 0.7 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 0 0.0 2 1.3 52 3.9
Hepatitis B, chronic 3 8.4 17 11.4 201 15.0
SAGADAHOC COUNTY
35,634
Of Maine’s Total 
Population 
2.7%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 0 0.0 1 0.7 39 2.9
Hepatitis C, chronic 24 67.4 214 143.2 1872 139.9
HIV 0 0.0 4 2.7 30 2.2
Invasive Pneumococcal Disease 5 14.0 15 10.0 132 9.9
Jamestown Canyon virus 0 0.0 1 0.7 1 0.1
Legionellosis 0 0.0 2 1.3 34 2.5
Listeriosis 0 0.0 0 0.0 7 0.5
Lyme disease 47 131.9 292 195.4 1405 105.0
Malaria 0 0.0 0 0.0 9 0.7
Mumps 0 0.0 0 0.0 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 15 42.1 87 58.2 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 7 19.6 27 18.1 152 11.4
Rabies, animal 7 NA 16 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
6 16.8 26 17.4 243 18.2
Salmonellosis 7 19.6 19 12.7 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
4 11.2 6 4.0 37 2.8
Shigellosis 1 2.8 1 0.7 7 0.5
Spotted Fever Rickettsiosis 0 0.0 3 2.0 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 0 0.0 12 0.9
Syphilis 3 8.4 9 6.0 104 7.8
Tuberculosis 0 0.0 0 0.0 14 1.0
Varicella (Chickenpox) 1 2.8 20 13.4 252 18.8
Vibriosis 0 0.0 2 1.3 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
42   |   2018 Reportable Infectious Diseases Summary
Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 10 19.8 67 38.8 476 35.6
Babesiosis 0 0.0 5 2.9 101 7.5
Borrelia miyamotoi 0 0.0 2 1.2 8 0.6
Campylobacteriosis 8 15.8 33 19.1 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
1 2.0 8 4.6 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 154 304.4 518 300.0 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 7 13.8 12 6.9 60 4.5
Dengue 0 0.0 0 0.0 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 6 3.5 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 4 2.3 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 8 15.8 20 11.6 163 12.2
Gonorrhea 12 23.7 59 34.2 686 51.3
Group A Streptococcus, invasive 3 5.9 10 5.8 85 6.4
Haemophilus influenzae, invasive 0 0.0 0 0.0 24 1.8
Hepatitis A, acute 2 4.0 2 1.2 9 0.7
Hepatitis B, acute 1 2.0 2 1.2 52 3.9
Hepatitis B, chronic 2 4.0 6 3.5 201 15.0
SOMERSET COUNTY
50,592
Of Maine’s Total 
Population 
3.8%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 3 5.9 3 1.7 39 2.9
Hepatitis C, chronic 65 128.5 212 122.8 1872 139.9
HIV 2 4.0 4 2.3 30 2.2
Invasive Pneumococcal Disease 6 11.9 24 13.9 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 2 4.0 5 2.9 34 2.5
Listeriosis 1 2.0 2 1.2 7 0.5
Lyme disease 45 88.9 226 130.9 1405 105.0
Malaria 0 0.0 1 0.6 9 0.7
Mumps 1 2.0 1 0.6 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 11 21.7 26 15.1 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 8 15.8 23 13.3 152 11.4
Rabies, animal 1 NA 10 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
9 17.8 34 19.7 243 18.2
Salmonellosis 3 5.9 10 5.8 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
2 4.0 7 4.1 37 2.8
Shigellosis 0 0.0 0 0.0 7 0.5
Spotted Fever Rickettsiosis 0 0.0 3 1.7 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 1 0.6 12 0.9
Syphilis 5 9.9 14 8.1 104 7.8
Tuberculosis 0 0.0 0 0.0 14 1.0
Varicella (Chickenpox) 10 19.8 22 12.7 252 18.8
Vibriosis 0 0.0 0 0.0 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
44   |   2018 Reportable Infectious Diseases Summary
Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 23 57.9 182 121.8 476 35.6
Babesiosis 6 15.1 30 20.1 101 7.5
Borrelia miyamotoi 0 0.0 5 3.3 8 0.6
Campylobacteriosis 6 15.1 27 18.1 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
2 5.0 11 7.4 92 6.9
Chikungunya Virus 0 0.0 1 0.7 2 0.1
Chlamydia trachomatis infection 78 196.5 385 257.6 4346 324.7
Coccidioidomycosis 0 0.0 2 1.3 2 0.1
Cryptosporidiosis 4 10.1 8 5.4 60 4.5
Dengue 1 2.5 1 0.7 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 0 0.0 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 2 1.3 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 6 15.1 24 16.1 163 12.2
Gonorrhea 12 30.2 32 21.4 686 51.3
Group A Streptococcus, invasive 2 5.0 4 2.7 85 6.4
Haemophilus influenzae, invasive 0 0.0 1 0.7 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 0 0.0 2 1.3 52 3.9
Hepatitis B, chronic 5 12.6 17 11.4 201 15.0
WALDO COUNTY
39,694
Of Maine’s Total 
Population 
3.0%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 0 0.0 1 0.7 39 2.9
Hepatitis C, chronic 56 141.1 214 143.2 1872 139.9
HIV 1 2.5 4 2.7 30 2.2
Invasive Pneumococcal Disease 4 10.1 15 10.0 132 9.9
Jamestown Canyon virus 0 0.0 1 0.7 1 0.1
Legionellosis 0 0.0 2 1.3 34 2.5
Listeriosis 0 0.0 0 0.0 7 0.5
Lyme disease 78 196.5 292 195.4 1405 105.0
Malaria 0 0.0 0 0.0 9 0.7
Mumps 0 0.0 0 0.0 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 64 161.2 87 58.2 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 3 7.6 27 18.1 152 11.4
Rabies, animal 5 NA 16 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
6 15.1 26 17.4 243 18.2
Salmonellosis 3 7.6 19 12.7 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
2 5.0 6 4.0 37 2.8
Shigellosis 0 0.0 1 0.7 7 0.5
Spotted Fever Rickettsiosis 0 0.0 3 2.0 10 0.7
Streptococcal toxic-shock syndrome 0 0.0 0 0.0 12 0.9
Syphilis 3 7.6 9 6.0 104 7.8
Tuberculosis 0 0.0 0 0.0 14 1.0
Varicella (Chickenpox) 10 25.2 20 13.4 252 18.8
Vibriosis 0 0.0 2 1.3 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
46   |   2018 Reportable Infectious Diseases Summary
Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 1 3.2 16 18.5 476 35.6
Babesiosis 1 3.2 6 7.0 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 4 12.7 16 18.5 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
1 3.2 1 1.2 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 94 298.5 220 254.9 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 1 3.2 3 3.5 60 4.5
Dengue 0 0.0 0 0.0 3 0.2
Ehrlichiosis, chaffeensis 0 0.0 0 0.0 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 0 0.0 0 0.0 9 0.7
Emerging Infection 0 0.0 0 0.0 1 0.1
Giardiasis 1 3.2 8 9.3 163 12.2
Gonorrhea 4 12.7 15 17.4 686 51.3
Group A Streptococcus, invasive 3 9.5 8 9.3 85 6.4
Haemophilus influenzae, invasive 1 3.2 1 1.2 24 1.8
Hepatitis A, acute 0 0.0 0 0.0 9 0.7
Hepatitis B, acute 5 15.9 12 13.9 52 3.9
Hepatitis B, chronic 10 31.8 15 17.4 201 15.0
WASHINGTON COUNTY
31,490
Of Maine’s Total 
Population 
2.3%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 1 3.2 3 3.5 39 2.9
Hepatitis C, chronic 47 149.3 115 133.3 1872 139.9
HIV 0 0.0 4 4.6 30 2.2
Invasive Pneumococcal Disease 7 22.2 13 15.1 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 0 0.0 2 2.3 34 2.5
Listeriosis 0 0.0 0 0.0 7 0.5
Lyme disease 15 47.6 189 219.0 1405 105.0
Malaria 0 0.0 1 1.2 9 0.7
Mumps 0 0.0 0 0.0 4 0.3
Neisseria meningitidis, invasive (Mening. 
disease)
0 0.0 0 0.0 1 0.1
Pertussis 1 3.2 32 37.1 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 10 31.8 12 13.9 152 11.4
Rabies, animal 5 NA 8 NA 76 NA 
S. aureus, methicillin resistant (MRSA), 
invasive
9 28.6 20 23.2 243 18.2
Salmonellosis 3 9.5 10 11.6 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
0 0.0 0 0.0 37 2.8
Shigellosis 0 0.0 0 0.0 7 0.5
Spotted Fever Rickettsiosis 1 3.2 2 2.3 10 0.7
Streptococcal toxic-shock syndrome 1 3.2 2 2.3 12 0.9
Syphilis 2 6.4 4 4.6 104 7.8
Tuberculosis 0 0.0 1 1.2 14 1.0
Varicella (Chickenpox) 4 12.7 13 15.1 252 18.8
Vibriosis 0 0.0 1 1.2 14 1.0
WNV, Non-Human 0 NA 0 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
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Counts of confirmed and probable cases. Rates of confirmed and probable cases per 100,000 people.
County District State
Condition Count Rate Count Rate Count Rate
Anaplasma phagocytophilum 84 40.7 84 40.7 476 35.6
Babesiosis 27 13.1 27 13.1 101 7.5
Borrelia miyamotoi 0 0.0 0 0.0 8 0.6
Campylobacteriosis 29 14.1 29 14.1 247 18.5
Carbapenem-resistant Enterobacteriaceae 
(CRE)
18 8.7 18 8.7 92 6.9
Chikungunya Virus 0 0.0 0 0.0 2 0.1
Chlamydia trachomatis infection 594 288.0 594 288.0 4346 324.7
Coccidioidomycosis 0 0.0 0 0.0 2 0.1
Cryptosporidiosis 9 4.4 9 4.4 60 4.5
Dengue 0 0.0 0 0.0 3 0.2
Ehrlichiosis, chaffeensis 1 0.5 1 0.5 19 1.4
Ehrlichiosis/Anaplasmosis, undetermined 1 0.5 1 0.5 9 0.7
Emerging Infection 1 0.5 1 0.5 1 0.1
Giardiasis 17 8.2 17 8.2 163 12.2
Gonorrhea 77 37.3 77 37.3 686 51.3
Group A Streptococcus, invasive 5 2.4 5 2.4 85 6.4
Haemophilus influenzae, invasive 4 1.9 4 1.9 24 1.8
Hepatitis A, acute 1 0.5 1 0.5 9 0.7
Hepatitis B, acute 8 3.9 8 3.9 52 3.9
Hepatitis B, chronic 16 7.8 16 7.8 201 15.0
YORK COUNTY
206,229
Of Maine’s Total 
Population 
15.4%
Population
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County District State
Condition Count Rate Count Rate Count Rate
Hepatitis C, acute 4 1.9 4 1.9 39 2.9
Hepatitis C, chronic 275 133.3 275 133.3 1872 139.9
HIV 3 1.5 3 1.5 30 2.2
Invasive Pneumococcal Disease 18 8.7 18 8.7 132 9.9
Jamestown Canyon virus 0 0.0 0 0.0 1 0.1
Legionellosis 5 2.4 5 2.4 34 2.5
Listeriosis 1 0.5 1 0.5 7 0.5
Lyme disease 201 97.5 201 97.5 1405 105.0
Malaria 1 0.5 1 0.5 9 0.7
Mumps 1 0.5 1 0.5 4 0.3
Neisseria meningitidis, invasive  
(Mening. disease)
0 0.0 0 0.0 1 0.1
Pertussis 173 83.9 173 83.9 446 33.3
Q fever 0 0.0 0 0.0 1 0.1
Rabies PEP 38 18.4 38 18.4 152 11.4
Rabies, animal 4 NA 4 NA 76 NA
S. aureus, methicillin resistant (MRSA), 
invasive
32 15.5 32 15.5 243 18.2
Salmonellosis 24 11.6 24 11.6 119 8.9
Shiga toxin-producing Escherichia coli 
(STEC)
8 3.9 8 3.9 37 2.8
Shigellosis 0 0.0 0 0.0 7 0.5
Spotted Fever Rickettsiosis 0 0.0 0 0.0 10 0.7
Streptococcal toxic-shock syndrome 3 1.5 3 1.5 12 0.9
Syphilis 22 10.7 22 10.7 104 7.8
Tuberculosis 0 0.0 0 0.0 14 1.0
Varicella (Chickenpox) 54 26.2 54 26.2 252 18.8
Vibriosis 4 1.9 4 1.9 14 1.0
WNV, Non-Human 3 NA 3 NA 5 NA
West Nile Fever 0 0.0 0 0.0 2 0.1
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DATA QUALITY WORKGROUP 
Maine’s Data Quality Workgroup meets every other week to review 
data quality of laboratory reports that are sent to Maine Center for 
Disease Control and Prevention (Maine CDC) with attention paid 
to those facilities that only send electronic lab reports (ELR). The 
Workgroup is chaired by Maine CDC’s Infectious Disease Informatician 
and other attendees are the Infectious Disease Program Director, 
Informatics Epidemiologist, and Influenza Surveillance Coordinator. 
The Data Quality Workgroup ensures that lab volumes are consistent 
and that all data feeds are running correctly. The group also reviews 
documents submitted by the labs that are looking to stop faxing paper 
lab reports and move to ELR only. In 2018, Maine CDC approved an 
additional facility to report only electronically bringing the total paper 
off reporters to six.
FOOD SAFETY WORKGROUP 
The Maine Interagency Food Safety Workgroup is led by Maine CDC’s 
Foodborne Disease Epidemiologist and is comprised of representatives 
from state agencies, federal agencies, and other organizations involved 
in improving food safety in Maine (including, but not limited to, Maine 
Department of Marine Resources (Maine DMR), Maine Department 
of Agriculture, Conservation, and Forestry (Maine DACF), Maine 
Department of Education (Maine DOE), United States Department 
of Agriculture (USDA), the Food and Drug Administration (FDA), and 
the University of Maine Cooperative Extension). These organizations 
and agencies collaborate to reduce the incidence of foodborne and 
waterborne infectious diseases in the state, respond to foodborne 
and waterborne outbreaks, and work together to advance food safety 
initiatives. The Workgroup meets quarterly during the year to discuss 
the latest developments and cooperate to improve response and 
prevention. It occasionally holds trainings for its member agencies and 
invites industry members to meetings to highlight common issues. 
Members of the Workgroup and Maine CDC infectious disease 
epidemiologists investigated a large waterborne outbreak of norovirus 
during the summer of 2018. Members of the Workgroup collaborated 
on several other outbreak investigations over the course of the year. 
Several members of the Workgroup presented at various conferences 
and meetings throughout the year, including the FDA Northeast 
Annual Food Protection Seminar in Portland in September 2018.
WORKGROUP SUMMARIES
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HEALTH EDUCATION WORKGROUP 
Maine CDC’s Health Education Workgroup started meeting in 
December of 2018 and meets every other month to address health 
education topics in public health. The Workgroup aims to strengthen 
skills such as health literacy, plain language, provider outreach, and the 
use of social media and infographics. This meeting also provides an 
opportunity to share resources and allows Maine CDC’s programs to 
be more interconnected. The Workgroup is chaired by Maine CDC’s 
Infectious Disease Health Educator and includes health educators and 
similar roles from Maine CDC’s Environmental and Occupational Health 
Program, HIV, STD, and Viral Hepatitis Program, Immunization Program, 
and Tobacco and Substance Use Prevention and Control Program. 
The Workgroup plans to expand in 2019 to include representation 
from other programs including Women, Infants, and Children Nutrition 
Program and the Suicide Prevention Program. 
INFLUENZA WORK GROUP
Maine’s Influenza Workgroup meets quarterly to address current topics 
in influenza and other viral respiratory pathogens. The Workgroup 
is chaired by the Influenza Surveillance Coordinator and includes 
representatives from Infectious Disease Epidemiology, Public Health 
Preparedness, the Maine Immunization Program, Public Health  
Nursing, Maine’s Health and Environmental Testing Laboratory (HETL), 
Maine DACF, and other relevant partners. The Workgroup coordinates 
surveillance and response to influenza and maintains and updates the 
Pandemic Influenza Operations Plan. The Influenza Workgroup also 
sponsors a start of influenza season conference call for healthcare 
providers and laboratories to update them on new guidance,  
reporting requirements, and assistance available from the State. 
WORKGROUP SUMMARIES
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RABIES WORKGROUP
The Maine Rabies Workgroup meets quarterly to address current topics 
in statewide rabies prevention and management. The Workgroup, 
co-chaired by the State Epidemiologist and the State Veterinarian, 
is comprised of animal and human health representatives from local, 
state, and federal agencies whose mission is to control the spread of 
rabies, a fatal zoonotic disease that is endemic in Maine. Agencies 
and organizations that participate in the Workgroup include, but are 
not limited to: Maine CDC, Maine DACF, HETL, Maine Department of 
Inland, Fisheries, and Wildlife (Maine IF&W), USDA, Maine Veterinary 
Medical Association, Maine Federation of Humane Societies, and the 
Maine Animal Control Association. 
Members of the Workgroup provide training to town animal control 
officers and game wardens regarding rabies biology and prevention 
and control of the disease in Maine. The USDA’s Animal and Plant 
Health Inspection Service distributes oral rabies vaccines in northern 
and eastern areas of the state with the goal to reduce the incidence 
of raccoon rabies. In 2018, the Workgroup introduced and piloted the 
Mail-A-Bat program at five vet clinics across the state. The Workgroup 
provided clinics with shipping material to mail bats to HETL for rabies 
testing. After a successful trial, the Workgroup hopes to expand this 
program to more vet clinics in future years.
SYNDROMIC SURVEILLANCE USER GROUP
Maine’s Syndromic Surveillance User Group meets every other month 
to address topics related to syndromic surveillance such as opioid 
overdose and influenza like illness (ILI) related emergency department 
visits as well as provide training on the use of available tools such 
as the Electronic Surveillance System for the Early Notification of 
Community-based Epidemics (ESSENCE). The User Group is chaired by 
the Informatics Epidemiologist and includes partners from within Maine 
CDC, Substance Abuse and Mental Health Services Administration 
(SAMSHA), Emergency Medical Services (EMS) as well as hospitals 
around Maine. The Group started meeting in April 2018 and provided 
several trainings for ESSENCE. The Group also worked together to 
create dashboards which have trend-over-time graphs and maps for 
topics that are of interest to the Group such as influenza-like illness  
and drug overdose syndromes. 
WORKGROUP SUMMARIES
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VECTORBORNE WORKGROUP 
Maine’s Vectorborne Workgroup meets every other month to address 
current topics in vectorborne diseases including illnesses spread 
by ticks, mosquitoes, and vectors of other medical importance 
like browntail moths. The Workgroup is chaired by the Infectious 
Disease Epidemiology Program Director at Maine CDC and includes 
representatives from epidemiology, environmental health, HETL, 
Maine DACF, Maine DOE, Maine Department of Environmental 
Protection, Maine Medical Center Research Institute, University of  
Maine Cooperative Extension, Maine IF&W, the Biodiversity Research 
Institute, pest control companies, and other relevant individuals. 
Subcommittees include the Wildlife Subcommittee which works  
on issues like deer density, the Messaging Committee which works  
on creating and standardizing information for common questions,  
and the Education Subcommittee which works on outreach. The 
Workgroup coordinates mosquito and tick surveillance within the  
state, and supports Lyme Disease Awareness Month in May.
The committee also launched a new mosquito messaging  
website with commonly asked questions, their answers, and the 
references that back the answers up. This website can be viewed  
at www.maine.gov/dhhs/mosquitofaq.
WORKGROUP SUMMARIES
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On July 10, 2018, a group of doctors and hepatitis specialists from 
Maine sent a letter to MaineCare, Maine’s Medicaid program, 
advocating for the removal of the sobriety barrier for hepatitis C 
treatment for MaineCare patients. This letter prompted MaineCare  
to request Maine CDC’s Viral Hepatitis Prevention Program to present 
information on studies related to sobriety barriers for hepatitis C 
treatment to MaineCare’s Drug Utilization Review Committee. The 
Committee voted unanimously to remove the sobriety barrier, and on 
October 1, 2018, MaineCare clients were no longer required to prove 
sobriety to receive treatment for hepatitis C. 
Previously, MaineCare required clients to be sober from alcohol  
and illicit drugs for six months before receiving hepatitis C treatment. 
However, multiple studies show that sobriety restrictions are 
unnecessary and undermine public health efforts to end the hepatitis 
C epidemic.1,2 In addition, removing sobriety barriers to hepatitis C 
treatment can result in lower medical costs to the state.3 The cost of 
treating hepatitis C when diagnosed is far less expensive than treating 
liver disease or performing liver transplants, for which hepatitis C is the 
leading cause.4,5 
Studies show that hepatitis treatment medication is just as effective 
in people who use drugs (PWUD) or alcohol as it is in people who do 
not, and PWUD adhere to treatment at the same rates as non-drug 
using individuals.6,7,8,9,10,11 Also, hepatitis C treatment for PWUD can 
lead to significant reductions in hepatitis C prevalence and reduced 
transmissions. Furthermore, the risk of reinfection for PWUD is less 
than 4%.9,12
Sobriety restrictions come with legal and financial risks. Several 
states with sobriety barriers for hepatitis C treatment in their 
Medicaid programs have lost costly lawsuits for not providing this 
treatment.13,14,15,16 Currently, at least half of all state Medicaid programs 
do not require individuals to meet sobriety criteria before obtaining 
treatment.17 Lessons learned from the HIV epidemic of the 1980s and 
1990s showed that having health insurance coverage and access to 
treatment was crucial in ending those epidemics.18,19 Maine CDC’s 
Viral Hepatitis Prevention Program continues to provide information 
to healthcare providers, state agencies and the public to help end the 
hepatitis C epidemic. 
MaineCare clients  
are no longer required 
to prove sobriety to 
receive treatment for  
hepatitis C. 
REMOVING BARRIERS TO HEPATITIS C 
TREATMENT IN MAINE
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https://stateofhepc.org/wp-content/uploads/2017/10/State-of-
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10  Aspinall EJ, Corson S, Doyle JS, et al., Treatment of hepatitis C 
virus infection among people who are actively injecting drugs: a 
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LYME DISEASE  
SOCIAL MEDIA CAMPAIGN 
The Public Health Corps (PHC), within Maine CDC’s Division of Disease 
Surveillance, designed and launched a Lyme disease social media 
campaign aimed at adults 65 years and older. The campaign targeted 
this specific age group because adults ages 65 years and older have the 
highest rate of Lyme disease in Maine. The PHC conducted a literature 
review and found that best practices for public health social media 
campaigns include the use of videos less than 44 seconds, pictures, and 
mascots. Mascots are beneficial in messaging since they help brand the 
campaign and allow users to quickly recognize the material. Maine CDC 
worked with a graphic designer to create four video slideshows, a static 
photo advertisement, and a mascot for the campaign (Image 1).
In August 2018, Maine CDC posted each advertisement for one week as Facebook boosted posts, Facebook 
sponsored advertisements, and YouTube paid instream video advertisements. Maine CDC spent $9,298.42 
in total on the campaign. To determine the number of views and reach of each advertisement, Maine CDC 
looked at Google and Facebook analytics. 
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Views by Dissemination Method
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Within the Target Population
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Facebook boosted posts generated an average of 
51,852 views and reached 46,370 people. Facebook 
sponsored advertisements generated an average 
of 16,073 views and reached 25,304 people. The 
Facebook sponsored static advertisement reached 
40,175 people. There are no data available on 
the average number of views for Facebook static 
advertisements since they are viewed differently 
than videos. YouTube paid instream advertisements 
generated an average of 46,377 views and reached 
104,021 people. Maine CDC found that YouTube 
paid instream advertisements and Facebook 
boosted posts reached more people and generated 
the most views (Chart 1). YouTube paid instream 
advertisements generated the most views when 
Maine CDC selected to advertise to both the 
target age group and users with an unknown age. 
Facebook boosted posts and Facebook sponsored 
advertisements reached the most people within the 
target population (Chart 2). 
Maine CDC found that each advertisement method 
had strengths and weaknesses. YouTube paid 
instream advertisements work best to reach the 
general public, while Facebook boosted posts work 
best to reach an age-specific target population. 
The Facebook static advertisement had more views 
than Facebook sponsored advertisements, although 
the static advertisement reached less of the target 
population. Maine CDC will use this information to 
inform future social media campaigns to maximize 
the reach of the information to target populations.
2018 Highlights
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There is an increase in cases of sexually transmitted infections (STIs) in 
the United States, as well as in the state of Maine. From 2016-2017, 
Maine saw an increase of 30% for gonorrhea and 77% for infectious 
syphilis. There was another increase from 2017-2018, with a 19% 
increase in gonorrhea and a 25% increase in infectious syphilis. There 
are many hypotheses of why STIs are increasing nationally, including: 
better surveillance, increased testing, reduced condom use, and 
an upsurge in popularity of dating apps which may increase one’s 
sexual network. Transmission is further amplified by the high rates 
of undiagnosed asymptomatic STIs, or STIs that are left untreated/
untested because they are in exposure sites that are not typically tested 
(pharyngeal or rectal). Rapid detection of STIs is crucial in reducing the 
incidence of STIs in Maine. Some health consequences of untreated 
STIs include: stillbirths, ectopic pregnancy, pelvic inflammatory disease, 
infertility and an increased risk for HIV transmission. 
EXTRAGENITAL TESTING:  
POTENTIAL SOLUTIONS TO CURB THE 
INCIDENCE OF STI INFECTIONS IN MAINE
Rapid detection  
of STIs is crucial  
in reducing the 
incidence of STIs  
in Maine.
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1 Center for Disease Control and Prevention. (2015). Special Populations - 2015 STD Treatment Guidelines.” Centers for Disease Control and 
Prevention, www.cdc.gov/std/tg2015/specialpops.htm.
2 Danby, C. S., Cosentino, L. A., Rabe, L. K., Priest, C. L., Damare, K. C., Macio, I. S., Meyn, L. A., Wiesenfeld, H. C., … Hillier, S. L. (2016). 
Patterns of Extragenital Chlamydia and Gonorrhea in Women and Men Who Have Sex With Men Reporting a History of Receptive Anal 
Intercourse. Sexually transmitted diseases, 43(2), 105-9. 
3 Centers for Disease Control and Prevention. Detailed STD Facts - HIV/AIDS & STDs. (2014). Centers for Disease Control and Prevention, 
www.cdc.gov/std/hiv/stdfact-std-hiv-detailed.htm.
It is possible that providers are missing asymptomatic 
STIs that present in extragenital sites of exposure. 
The federal CDC’s current recommendations state 
that men who have sex with men (MSM) who have 
had receptive anal or oral sex be screened using the 
Nucleic Acid Amplification Test (NAAT) annually1. 
Medical providers should take thorough sexual 
health histories to assess if an individual should 
be tested more frequently. Studies indicate that 
genitourinary screening alone for MSM has the 
potential to miss 80% of chlamydia and 77% of 
gonorrhea infections2. Research shows that medical 
providers are screening regularly for syphilis among 
HIV positive MSM but are screening less than 10% 
of HIV positive MSM for gonorrhea and chlamydia 
(rectal and pharyngeal).1 Anal chlamydia and 
gonorrhea infections are associated with a greater 
risk of acquiring HIV. One-in-ten new HIV cases 
among MSM are due to the presence of chlamydia 
and gonorrhea infection3. Maine 2018 data indicate 
that rectal and pharyngeal STI testing only represent 
about 1% of total STI testing (8% of STI testing had 
no specimen description listed). Potential barriers 
to lack of extragenital testing could be physicians’ 
comfort level in taking sexual history and the fact 
that extragenital testing is not yet FDA approved. 
2018 Highlights
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EMERGING THREAT:  
CARBAPENEMASE-PRODUCING ORGANISMS
BACKGROUND:
While most bacterial resistance is acquired from prior exposure to antibiotics, there are some bacteria that 
can share their resistance genes directly with other bacteria, including bacteria of other genus and species. 
This type of bacterial resistance is known as plasmid-mediated resistance.
THE THREAT:
• Carbapenemase-producing organisms (CPO) are a subset of carbapenemase-resistant organisms (CRO) 
that are capable of plasmid-mediated resistance.
• CPOs are highly resistant to multiple classes of antibiotics, leaving clinicians with few treatment options.
• Infections with CPOs are associated with high mortality rates.
• A person can be colonized with a CPO and not be aware of it, potentially spreading it. 
• Hospitalization outside of the USA, including surgery and dialysis, in an CPO endemic country,  
is a significant risk factor for acquiring a CPO.
• CPOs are now found in every state in the USA, including Maine.
CARBAPENEM-RESISTANCE DEFINED:
Carbapenemase-producing organisms (CPO), are 
CROs that test positive for the carbapenemase-
producing enzyme or gene, signifying that 
resistance to the carbapenem antibiotic(s) is 
plasmid-mediated. CPOs can share their resistance 
genes directly with other bacteria and are 
considered a public health threat.
Carbapenem-resistant Organisms (CRO) are bacteria in the family Enterobacteriaceae (e.g. Citrobacter spp., 
Enterobacter spp., Escherichia coli, Klebsiella spp., Morganella morganii, Proteus spp., Providencia spp., 
Serratia spp., Salmonella spp., Shigella spp., Yersinia spp.), Pseudomonas aeruginosa and Acinetobacter 
baumannii that test resistant to one or more carbapenem antibiotics, regardless of the method of resistance.
Non carbapenemase-producing organisms  
(non-CPO), are those CROs that have undergone 
further laboratory testing and were found not to 
contain a carbapenemase-producing enzyme that 
breaks down the carbapenem antibiotics or the gene 
(e.g. IMP, KPC, NDM, OXA-48, VIM) that produces 
the carbapenemase enzyme. Therefore, resistance to 
the carbapenem antibiotic(s) is acquired resistance.
CRO 
Carbapenem-resistant
Non-CPO 
Acquired resistance
CPO 
Plasmid-mediated resistance
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PREVENTION:
• Hand hygiene is still the best prevention.
• Clean and disinfect patient rooms and equipment.
• Follow contact precautions for known patients colonized  
or infected with a CPO.
• Practice good antimicrobial stewardship. 
HEALTHCARE FACILITIES SHOULD NOTIFY  
MAINE CDC AT 1-800-821-5821 WHEN:
• A CRO is identified (and send the isolate to the state public  
health laboratory)
• Healthcare associated transmission of a CRO is suspected
Carbapenemase-
producing organisms 
are emerging multi-
drug resistant bacteria 
that present a serious 
health threat for the 
people of Maine.
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MAINE’S RYAN WHITE PART B AND AIDS  
DRUG ASSISTANCE PROGRAM
The Ryan White Part B Program helps low-income people living with HIV (PLWH) in Maine fill gaps in 
care and treatment by providing a variety of services, depending on individual need, with the ultimate 
goal being the achievement and maintenance of viral suppression. The Ryan White Part B Program 
helps low-income PLWH access food, dental care, and housing. The Program also supports medical case 
management for those who do not qualify for other types of case management, and administers the 
AIDS Drug Assistance Program (ADAP), which helps low-income PLWH obtain and maintain access to 
prescription drugs to treat HIV and its related conditions. ADAP services include assistance with health 
insurance premiums, copays, deductibles, coinsurance, HIV-related lab tests, and the full cost of HIV-
related drugs for those without insurance.  
People Living with HIV Utilizing Ryan White Part B Services, 2015-2018
Service 2015 2016 2017 2018
Dental assistance 183 180 279 293
Food assistance 497 522 579 584
Full-cost drugs 110 120 106 118
Housing assistance 168 199 257 304
Insurance premiums 208 190 240 299
Lab tests 14 20 24 25
Medical case management 87 90 97 101
Prescription wrap-around 626 602 544 560
Total utilizing members 882 923 939 987
 
PLWH who are virally suppressed (defined as a viral load test result less than 200 copies/mL) are less likely 
to develop HIV-related complications, so they lead longer, healthier lives and require less costly care and 
treatment. PLWH who are virally suppressed are much less likely to transmit the virus to others. The National 
HIV/AIDS Strategy calls for viral suppression among 80 percent of all PLWH in the U.S. by 2020. In 2018, 90 
percent of Part B Program enrollees were virally suppressed as of the last result reported in 2018, compared 
to 85 percent of enrollees in 2017. 
www.maine.gov/idepi   |   63
2018 Highlights
Viral Suppression Among Ryan White Part B Enrollees by Public Health District, 2018
District
Number Virally 
Suppressed
Number  
Enrolled
% Virally  
Suppressed
Aroostook 27 29 93%
Central 123 142 87%
Cumberland 354 386 92%
Downeast 70 78 90%
Mid Coast 64 69 93%
Penquis 81 86 94%
Western 126 151 83%
York 133 146 91%
Overall 978 1,087 90%
90%
of people living with HIV 
enrolled in Maine’s Ryan 
White Part B Program were 
virally suppressed in 2018.
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POND OUTBREAK 
CUMBERLAND COUNTY JULY 2018
On Friday July 6, 2018 a member of the public contacted Maine CDC about family and friends who became 
ill with gastrointestinal symptoms after visiting a public beach on Woods Pond, operated by the Town of 
Bridgton, Maine. Given the gastrointestinal (GI) symptoms and the epidemiology described in the initial 
report, an outbreak team quickly formed to investigate. Maine CDC notified and worked closely with local 
hospitals and officials to investigate this outbreak. Based on information provided to town officials, the Town 
of Bridgton closed the public beach on July 6. 
Using the initial information provided, Maine CDC’s Cumberland Field Epidemiologist conducted open 
ended interviews with seven heads of households to generate a list of questions for a wider attendee survey. 
The Foodborne and Waterborne Epidemiologist added exposures of note to a modified version of the 
Division of Disease Surveillance’s Foodborne/Enteric Disease survey template. The Maine CDC interview 
team consisted of five epidemiologists and one public health educator. The interview team used this survey 
to collect information about individuals’ exposures, symptoms, and duration of illness.
Using the Maine CDC Facebook page, Maine CDC issued a call for cases and identified additional 
individuals who visited the pond between July 1 – July 6, 2018. In many circumstances, the heads of 
households provided answers for multiple family members. The interview team entered interview data into a 
spreadsheet, and the Foodborne and Waterborne Epidemiologist analyzed these using Epi Info 7 statistical 
software. Maine CDC asked ill respondents to submit stool specimens for viral and bacterial testing at 
Maine’s Health and Environmental Testing Laboratory (HETL). New York State Wadsworth Center Virology 
Laboratory assisted in confirming test results as needed.
Maine CDC consulted with the federal Centers for Disease Control and 
Prevention (CDC) regarding testing the pond’s water if the outbreak 
team deemed it appropriate. The outbreak team also discussed 
additional testing and epidemiology strategies. Maine CDC decided 
testing of the pond water would not be useful given the circumstances 
of the outbreak. 
After the call for additional cases, Maine CDC interviewed a total of 
thirty-four (34) heads of household by phone and collected data on 148 
people who visited the pond or were exposed to ill individuals at home. 
139 people reported attending the pond between July 1 – July 6. Of 
those who visited the pond, 97 people reported being sick (attack rate: 
69.8%). Pond visitors who went under the water or swallowed the water 
while swimming were over three times more likely to be sick than those 
who did not (relative risk = 3.19, p < 0.001). There were no significant 
relative risks for other exposures such as using the playground and 
eating or drinking at the beach. 
3X
Swimmers who went under  
water were 3 times more  
likely to become ill.
69.8%
Attack Rate
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Maine CDC confirmed 
this as a continuous 
common source 
waterborne outbreak 
of norovirus with 
secondary person-to-
person transmission.
Health care providers collected four (4) human stool specimens for 
bacterial and viral testing that was performed at HETL. Two out of 
four human stool specimens tested positive for Norovirus GI. Based 
on collected data and two positive human specimens, Maine CDC 
confirmed this as a continuous common source waterborne outbreak  
of norovirus with secondary person-to-person transmission.  
Although Maine CDC associated the outbreak with swimming 
underwater at the beach, Maine CDC was unable to determine the 
source of the norovirus. There may have been numerous sources for 
contamination that resulted in a high number of ill individuals. The 
town of Bridgton reopened the public beach on July 10, 2018 and no 
additional individuals reported illnesses associated with this outbreak.
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CAKE OUTBREAK 
ANDROSCOGGIN COUNTY JUNE 2018
On Monday June 25, 2018 a Hospital Infection Preventionist (IP) notified Maine CDC of a gastrointestinal 
outbreak seemingly stemming from a work party event held on Thursday, June 21 at a private medical 
practice in Androscoggin County. Maine CDC’s Western District Field Epidemiologist began collecting 
information about the outbreak and notified the Foodborne Epidemiologist who convened an outbreak 
investigation team.  
The work party consisted of approximately 40 attendees; 21 had been or were currently ill with nausea, 
vomiting, and diarrhea. Many of the ill individuals had symptom onset on Friday, June 22 and Saturday, 
June 23. Average duration of illness was approximately two days. Employees attending the party brought 
in food for the potluck including: taco salad, homemade cookie cake, ice cream, assorted dips and chips, 
seven-layer dip, meatballs, strawberries stuffed with cheesecake filling, rotisserie chicken, potato salad, 
pasta salad, and soda. 
Using this list, epidemiologists designed and administered a customized survey to better collect exposure 
and illness information. The Western District Field Epidemiologist interviewed 23 employees in person 
at the office, and other epidemiologists interviewed another 15 attendees by telephone. The Foodborne 
Epidemiologist analyzed the data collected from the surveys to look for statistically significant exposures that 
may have led to these illnesses. Those who ate or came in to contact with the cookie cake were more than 
eight (8) times more likely to be ill (relative risk = 8.34 [1.27 - 54.69], p < 0.0002) than those who did not. 
Contact included eating, serving, cooking, preparing, and disposing of the cake. Epidemiologists found no 
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50%
Number of attendees who  
had been or were currently ill.
8X
Attendees who came in contact  
with the cake were 8 times more 
likely to become ill.
other food exposures significantly associated with illness. The employee 
who brought the homemade cookie cake to the potluck said that 
multiple family members were ill during the previous week. 
One attendee submitted a stool specimen to Maine’s Health and 
Environmental Testing Laboratory (HETL) for bacterial and viral testing. 
Epidemiologists collected leftover food from the office and brought 
it to HETL, and laboratorians sampled parts of the cookie cake for 
norovirus testing. All of the cake components tested negative for 
norovirus, but the one human specimen submitted tested positive 
for norovirus GII. Testing for norovirus in food is challenging, so the 
absence of norovirus in the cake sample did not mean that other parts 
of the cake were not contaminated.
In conclusion, epidemiologists classified this outbreak as a probable 
norovirus outbreak associated with consuming or coming into contact 
with the cookie cake at the party. Epidemiologists were able to provide 
a strong epidemiological link between illness and consumption of the 
cake despite the negative results on the cake samples tested. The 
Western District Field Epidemiologist shared these findings with the 
office and provided guidance on safe food handling practices, staying 
out of work while ill, not preparing food for others while ill, and general 
sanitation practices.  
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RABIES POST-EXPOSURE PROPHYLAXIS (PEP)  
IN MAINE, 2018
Animal rabies is endemic in Maine and every year humans are exposed to rabid or potentially rabid animals. 
Rabies is 100% fatal if left untreated, but can be prevented when treated promptly after an exposure to 
the rabies virus. Recommendations for individuals to receive rabies treatment after an exposure to the 
rabies virus depend on the circumstances surrounding the exposure. The treatment is called rabies post-
exposure prophylaxis (PEP), and it involves a series of rabies vaccines and rabies immune globulin (RIG) 
shots. Healthcare providers are required by Maine law to report rabies PEP to Maine CDC within 48 hours of 
administration, but many providers fall short of this requirement. For this reason, the reported cases of rabies 
PEP in Maine does not accurately represent the true number of rabies PEP given statewide. 
Maine CDC considers a case of rabies PEP when a person either receives a treatment recommendation, 
begins treatment, or both. In 2018, Maine reported 152 cases of rabies PEP. 96% (146 reported cases) 
went to a healthcare provider or emergency department to begin their treatment. Six individuals received 
recommendations, but did not begin rabies PEP. One individual refused treatment. One individual no longer 
needed treatment because the attacking animal was ruled rabies free. Four individuals were lost to follow-up.
Rabies PEP is considered a medical urgency, but not a medical emergency. In many cases, rabies PEP can 
wait until the response measure (either quarantine or testing) for the attacking animal is completed. Of 
the 146 individuals who began rabies PEP, 37% (57 individuals) received rabies PEP because the attacking 
animal could not be located after the exposure and 23% (34 individuals) received rabies PEP because the 
attacking animal tested positive or unsatisfactory for rabies. Other reasons for the administration for rabies 
PEP include, but are not limited to, possible exposures to bats, contact with mucous membranes, or a severe 
attack to the head or neck.
Rabies PEP is readily available, but often in short supply. For this reason, healthcare providers must 
individually evaluate each suspected human exposure to a potentially rabid animal. Rabies exposures are 
rarely clear-cut issues, so treatment decisions must consider a variety of factors. These factors include type 
of exposure, extent or severity of exposure, type of animal species involved, animal vaccination status, 
circumstances leading to exposure, availability of animal for confinement and observation or testing, and the 
epidemiology of rabies in the region. 
Cases of Rabies PEP by Animal Encountered
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Generally, Maine CDC will recommend rabies PEP in cases where an animal tests positive for rabies, a high-risk 
animal is unavailable for quarantine or testing, or when serious attacks occur to the head, face, or neck. This 
is not a hard-set rule, but a guide as most people who are exposed to a potentially rabid animal still require a 
thorough evaluation. 37% of the 152 exposures in 2018 occurred to a hand or finger while 11% occurred to a 
leg, 8% to an arm, and 7% to the head or neck. In 7% of cases, exposures occurred to two or more regions of 
the body. About 30% of exposure sites were unknown.
Of the 152 animal exposures, bats were by far the most frequent animal encountered accounting for almost 
40% of all cases of rabies PEP. Wild animal encounters made up 69% of all exposures followed by stray animal 
exposures at 22% and owned animal exposures just under 9%. 
Status Animal Rabies PEP
Wild
Bat 60
Bear 1
Ermine 1
Fox 15
Mouse 1
Raccoon 20
Skunk 4
Squirrel 3
Owned
Cat 4
Dog 9
Stray
Cat 23
Dog 10
Unknown Unknown 1
Total 152
Cases of Rabies PEP by Animal Encountered  
Reported to Maine CDC, 2018
Rabies PEP is typically not required when 
pets bite humans because pets are typically 
available for confinement and observation. In 
2018, 13 individuals received rabies treatment 
after a bite from an owned pet. In 31% of these 
cases, the pet’s owner fled with the pet after 
the attack and in another 31% because the 
pet died within the days of exposure. Other 
situations why people received treatment 
after an exposure to a pet include, but are not 
limited to, owners provoking their pets, people 
exposed by someone else’s pet while on a trip 
or camping, or pet could not be identified. 
Maine CDC normally does not recommend 
rabies PEP for encounters with small rodents 
like mice and squirrels because it is generally 
understood that small mammals are highly 
unlikely to survive an attack from a commonly 
rabid animal. Thus, it is unlikely for this group 
of mammals to transmit the rabies virus. Only 
in one rabies PEP case was the animal type and 
status unknown. 
Maine CDC and Maine Department of 
Agriculture, Conservation, and Forestry, 
together with the Maine Rabies Workgroup, 
produce the Maine Rabies Management 
Guidelines. To review these guidelines and 
other resources, please visit  
www.maine.gov/dhhs/rabies.
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EVALUATION OF THE MAINE  
VARICELLA SURVEILLANCE SYSTEM 
BACKGROUND
In 2002, federal CDC encouraged states to develop case-based varicella surveillance systems by 2005  
to help monitor changing trends in varicella epidemiology following the implementation of a routine 
varicella immunization schedule. Varicella surveillance aims to document the impact of varicella vaccine  
on varicella related morbidity and mortality, evaluate the effectiveness of prevention strategies, and 
evaluate vaccine effectiveness. 
The Maine varicella surveillance system relied on passive case reports from healthcare providers, school 
nurses, and laboratories. Maine investigated all cases of varicella reported by a provider and all hospitalized 
or invasive cases of varicella zoster in patients over the age of 18 (determined by lab specimen source and/or 
patient status in lab report). Maine does not investigate other laboratory reports of varicella zoster in patients 
over the age of 18 but counts them as cases in the surveillance system. Maine classifies those with PCR or 
IgM positive labs as cases. Maine considers these cases of varicella to be “non-investigated varicella cases”. 
METHODS
In 2018, the Maine vaccine preventable disease (VPD) epidemiologist reviewed varicella surveillance 
as part of the VPD program evaluation. The VPD epidemiologist validated every reporting source and 
created a process to test the accuracy of case classification for non-investigated varicella cases. The VPD 
epidemiologist pulled all non-investigated cases of varicella from Maine’s electronic case database. An 
epidemiologist followed up on selected cases by calling the associated physician to get clinical information  
about the case and determine if the patient met the surveillance case classification for varicella. 
RESULTS
Since 2012, Maine averaged 117 non-investigated varicella cases per year. The proportion of non-investigated 
varicella cases averaged 57% of all cases (Table 1). 
 
Table 1. Investigated and non-investigated varicella cases, by year
2012 2013 2014 2015 2016 2017 2018
Investigated 
varicella cases
170
(65.9 %)
47
(33.6 %)
58
(28.0 %)
92
(39.5 %)
113
(49.6 %)
85
(42.9 %)
132
(52.4 %)
Non-investigated 
varicella cases
88 
(34.1 %)
93
(66.4 %)
149
(72.0 %)
141
(60.5 %)
115
(50.4 %)
113
(57.1 %)
120
(47.6 %)
Total varicella 
cases
258
(100%)
140
(100%)
207
(100%)
233
(100%)
228
(100%)
198
(100%)
252
(100%)
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In 2018, the VPD epidemiologist identified 120 non-investigated 
varicella cases and randomly selected 63 cases for follow-up. None of 
the 63 cases investigated met the varicella case definition. Forty-six of 
the 63 cases (73%) had shingles, six (10%) had titers drawn to check for 
immunity, and ten (16%) had other non-varicella diagnoses without a 
diffuse rash. 
CONCLUSIONS
The results of the investigation showed that classifying cases as varicella 
based only on laboratory results was inappropriate. Therefore, as of 
January 1, 2019, epidemiologists will review and document all varicella 
PCR positive or IgM positive laboratory results reported in adults 
>18 years but will not investigate or count the reports as cases unless 
providers specifically report the patients as cases or varicella-related 
deaths. This will greatly impact Maine varicella data, especially when 
comparing to previous years, but will improve accuracy and the Maine 
varicella surveillance system will reflect a better understanding of the 
true burden of varicella in the population. 
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INFLUENZA EDUCATION AMONG  
YOUTH IN AGRICULTURE
During the 2017-2018 influenza season Maine participated in a 
federally funded project aimed at educating youth in agriculture 
on influenza and other zoonotic diseases. This was done as a 
collaboration between Maine Center for Disease Control and 
Prevention (Maine CDC) and Maine Department of Agriculture, 
Conservation, and Forestry (Maine DACF). The goal of this project 
was to educate youth about zoonotic infections, deliver prevention 
messages to keep people and animals safe and healthy, and 
strengthen One Health networks among state human and animal 
health departments and agricultural communities.
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6-60
Number range of 
participants
37
Events completed  
or planned
700
Total Participants
TRAIN-THE-TRAINER EVENT:
In January 2018, Maine CDC and Maine DACF held a train-the-trainer event for 39 youth agricultural 
leaders. Attendees included representatives from 14 out of 16 counties in Maine and representatives from 
22 out of the 25 Maine annual agricultural fairs.  
This event provided direct instruction to youth agriculture leaders about diseases that can be transmitted 
between animals and humans, signs and symptoms of the diseases, and prevention strategies to reduce 
the risk of transmission. Maine CDC and Maine DACF delivered this information through presentations, 
interactive activities and group discussions. Maine encouraged attendees to teach and share the 
information with their local youth agriculture groups after the train-the-trainer event.
As of July 1, 2018, 37 of the 39 (95%) participants completed or planned a teaching event for youth. Of 
the completed events, the average number of participants was 22 with a range of 6-60 with over 700 
estimated total participants.
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